SCHEMBL800806

SCHEMBL800806

CCCCCC1NC(=O)c2coc(n2)-c2coc(n2)-c2coc(n2)C(C(C)C)NC(=O)c2coc(n2)-c2coc(n2)-c2coc1n2

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TERT O14746 4/20 0.65
CPB2 Q96IY4 2/20 0.35
ABCB1 P08183 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL800811 0.91 TERT (0.81) TERTCPB2ABCB1
SCHEMBL801061 0.89 TERT (0.62) TERTCPB2ABCB1
SCHEMBL800528 0.85 TERT (0.56) TERTCPB2ABCB1
SCHEMBL10045824 0.85 TERT (0.58) TERTCPB2
Hexaoxazole Divaline SCHEMBL800953 0.85 TERT (0.52) TERTCPB2ABCB1
SCHEMBL800910 0.79 TERT (1.00) TERTCPB2
SCHEMBL805246 0.79 ABCB1 (0.49) TERTCPB2ABCB1
SCHEMBL805228 0.78 TERT (0.45) TERTCPB2ABCB1
SCHEMBL805222 0.78 TERT (0.45) TERTCPB2ABCB1
SCHEMBL10072678 0.78 TERT (0.66) TERTCPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518928-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-08-27 US disclosed
US-20120071527-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071527-A1 THERAPEUTIC COMPOUNDS TOP2B, DDB1, TOP1 TERT 141/4885CPB2 4586/4885ABCB1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.